Optima Medical Innovations Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Optima Medical Innovations has been growing earnings at an average annual rate of 1.5%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 38% per year.
Anahtar bilgiler
1.5%
Kazanç büyüme oranı
43.1%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 23.1% |
| Gelir büyüme oranı | 38.0% |
| Özkaynak getirisi | -11.6% |
| Net Marj | -18.8% |
| Son Kazanç Güncellemesi | 30 Sep 2021 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Optima Medical Innovations nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 21 | 2 | 0 | 0 | 0 |
| 30 Jun 21 | 2 | 0 | 0 | 0 |
| 31 Mar 21 | 5 | -3 | 2 | 0 |
| 31 Dec 20 | 5 | -4 | 3 | 0 |
| 30 Sep 20 | 7 | -16 | 6 | 0 |
| 30 Jun 20 | 8 | -18 | 8 | 0 |
| 31 Mar 20 | 6 | -17 | 6 | 0 |
| 31 Dec 19 | 5 | -18 | 7 | 0 |
| 30 Sep 19 | 4 | -11 | 7 | 0 |
| 30 Jun 19 | 3 | -10 | 6 | 0 |
| 31 Mar 19 | 1 | -17 | 9 | 0 |
| 31 Dec 18 | 1 | -16 | 8 | 0 |
| 30 Sep 18 | 1 | -10 | 7 | 0 |
| 30 Jun 18 | 1 | -10 | 6 | 0 |
| 31 Mar 18 | 0 | -4 | 4 | 0 |
| 31 Dec 17 | 0 | -6 | 6 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Kaliteli Kazançlar: OMIC is currently unprofitable.
Büyüyen Kar Marjı: OMIC is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: OMIC is unprofitable, but has reduced losses over the past 5 years at a rate of 1.5% per year.
Büyüme Hızlandırma: Unable to compare OMIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: OMIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Özkaynak Getirisi
Yüksek ROE: OMIC has a negative Return on Equity (-11.58%), as it is currently unprofitable.